Royalty Pharma to Announce Second-Quarter 2020 Financial Results on August 12
21 July 2020 - 6:15AM
Royalty Pharma (NASDAQ: RPRX) today announced that it will report
its second quarter 2020 financial results on Wednesday, August
12, 2020, before the U.S. financial markets open. The Company
will host a conference call and simultaneous webcast at 8:00
AM Eastern Time that day.
Conference Call
Information
A link to the webcast may be accessed from the
'Investors' page of Royalty Pharma’s website or
at https://edge.media-server.com/mmc/p/2ujdenpf. Please
allow at least five minutes for registering and accessing the
presentation. A replay of the conference call and webcast
will be archived on the Company's website for at least 30
days.
To ask a question during the live broadcast or
listen without Internet access, please dial in at least 15 minutes
in advance to ensure a timely connection to the call. The
dial in number to join the call is (833) 519-1253 from within the
United States; the number for international callers is + 1 (914)
800-3826. Enter the passcode 6299563 when prompted.
About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest
buyer of biopharmaceutical royalties and a leading funder of
innovation across the biopharmaceutical industry, collaborating
with innovators from academic institutions, research hospitals and
not-for-profits through small and mid-cap biotechnology companies
to leading global pharmaceutical companies. Royalty Pharma has
assembled a portfolio of royalties which entitles it to payments
based directly on the top-line sales of many of the industry’s
leading therapies. Royalty Pharma funds innovation in the
biopharmaceutical industry both directly and indirectly - directly
when it partners with companies to co-fund late-stage clinical
trials and new product launches in exchange for future royalties,
and indirectly when it acquires existing royalties from the
original innovators. Royalty Pharma’s current portfolio includes
royalties on more than 45 commercial products, including AbbVie and
J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s
Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’
Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four
development-stage product candidates. For more information, visit
www.royaltypharma.com.
Royalty Pharma Investor Relations and
Communications
+1 (212) 883-2295ir@royaltypharma.com
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Apr 2024 to May 2024
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From May 2023 to May 2024